Chinese english Germany Korea


トラベクテジン 化学構造式
トラベクテジン;エクチナサイジン743;エクテイナシジン743;エクテイナスシジン743;トラベクテジン (JAN)
ecteinascidin 743
ET-743;Yondelis;NSC 648766;NSC-684766;Trabectedin;cteinascidin;Ecteinascidin;ecteinascidin 743;Ecteinascidine 743;Yondelis R ,Trabectedin
MOL File:

トラベクテジン 物理性質

比旋光度 :
D25 +114° (c = 0.1 in methanol)
比重(密度) :
1.55±0.1 g/cm3 (20 ºC 760 Torr)


トラベクテジン 価格 もっと(1)

メーカー 製品番号 製品説明 CAS番号 包装 価格 更新時間 購入
富士フイルム和光純薬株式会社(wako) W01TRCT703500 トラベクテジン
114899-77-3 10mg ¥11875000 2018-12-26 購入

トラベクテジン 化学特性,用途語,生産方法


抗悪性腫瘍薬, アルキル化剤


ヨンデリス (大鵬薬品工業)


Trabectedin is a marine natural product derived from the tunicate Ecteinascidia turbinate. With its demonstrated in vitro and in vivo activity against a range of solid tumor cell lines, human xenografts and tumor explants, this antineoplastic agent has been developed and launched for the treatment of advanced STS after failure of first-line therapy with anthracyclines or ifosfamide or in patients who are unsuited to receive these agents. Its proposed mechanism of action involves binding to the N2 position of guanine in the minor groove demonstrating a preference for sequences containing 5′-PuGC and 5′-PyGG motifs. Subsequent alkylation of DNA, via an iminium intermediate generated from an intra-molecular acid-catalyzed activation and dehydration of the carbinolamine, induces a curvature of the DNA toward the major groove that ultimately disrupts the binding of transcription factors involved in cell proliferation. Evaluation of trabectedin against the National Cancer Institute’s human in vitro cell line panel, including melanoma, non-small-cell lung, ovarian, renal, prostate, and breast cancer, demonstrated potencies ranging from 1 pM to 10 nM.


University of Illinois (US)


A tetrahydroisoquinoline alkaloid with antitumor activity isolated from the Caribbean tunicate, Ecteinascidin turbinata. It is the first marine anticancer agent approved in the European Union for patients with soft tissue sarcoma (STS).


ChEBI: A tetrahydroisoquinoline alkaloid obtained from a Caribbean tunicate Ecteinascidia turbinata. Used for the treatment of soft tissue sarcoma and relapsed ovarian cancer.

brand name



The most common adverse events included nausea, fatigue, vomiting, anorexia, neutropenia, and increases in aspartate aminotransferase and alanine aminotransferase liver enzymes. To combat the nausea and vomiting, all patients must receive 20mg of dexamethasone intravenously before the trabectedin infusion. Not only does this pretreatment have an antiemetic effect, it also appears to offer a hepatoprotective benefit. Concomitant administration of potent inhibitors and inducers of CYP3A4 should be avoided since plasma levels of this CYP3A4- metabolized drug will be affected. Trabectedin is contraindicated in patients with a known hypersensitivity to trabectedin, concurrent serious or uncontrolled infection, or breast-feeding. Trabectedin should also not be administered in combination with yellow fever vaccine. Finally, there are strict criteria regarding absolute neutrophil count, platelet count, and renal and hepatic enzyme levels for permission to initiate or continue treatment with trabectedin.

Chemical Synthesis

While the challenging total synthesis of trabectedin has been accomplished by a few research groups, the commercial preparation begins from readily available cyanosafracin B in 21 steps. Following the Boc and MOM protection of the amine and phenol functionalities, respectively, the methoxy-pquinone was hydrolyzed with sodium hydroxide in methanol. The resulting quinine was reduced (hydrogen over Pd/C) to give an unstable hydroquinone that was subsequently alkylated with bromochloromethane and allyl bromide. The MOM and Boc groups were then removed followed by cleavage of the amide by Edman degradation (through formation of the thiourea with phenyl isothiocyanate and treatment with HCl in 1,4-dioxane). At this point, the amine was protected as the TROC carbamate before reprotecting the phenol as the MOM ether and then liberating the amine with zinc in acetic acid. The amine was converted to an alcohol moiety with sodium nitrite in acetic acid, and this handle was acylated with (S)-N-[(trichloroethoxy)carbonyl]-S-(9-fluorenylmethyl)cysteine. Removal of the allyl-protecting group followed by oxidation provided an 492 Shridhar Hegde and Michelle Schmidt alpha-hydroxy ketone intermediate. Dehydration and deprotection of the cysteine established the Michael addition of the thiol to the o-quinone methide with concomitant trapping with acetic anhydride. The remaining steps involved removal of protecting groups, installation of the tetrahydroisoquinoline ring via a Pictet Spengler reaction, and conversion of the cyano to the alcohol of the carbinolamine with silver nitrate in acetonitrile and water.

トラベクテジン 上流と下流の製品情報



トラベクテジン 生産企業

Global( 69)Suppliers
名前 電話番号 ファックス番号 電子メール 国籍 製品カタログ 優位度
Henan DaKen Chemical CO.,LTD.
+86-371-55531817 CHINA 21714 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 20672 55
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 CHINA 24191 60
career henan chemical co
+86-371-86658258 CHINA 30002 58
Shaanxi Yikanglong Biotechnology Co., Ltd.
17791478691 CHINA 297 58
Chemwill Asia Co.,Ltd.
86-21-51861608;;; CHINA 23980 58
Hubei Jusheng Technology Co.,Ltd.
027-59599243 CHINA 28236 58
BOC Sciences
1-631-614-7828 United States 20115 58
Chongqing Chemdad Co., Ltd
+86-13650506873 CHINA 35440 58
WuYan Pharmaceutical Technology (Shanghai) Co., Ltd. 0512-53995837,13371908063
021-61114075 China 63 55


  • 114899-77-3
  • ecteinascidin 743
  • Trabectedin
  • (1'R,6R,6aR,7R,13S,14S,16R)-
  • ET-743
  • Yondelis
  • Trabectedin(Ecteinascidin 743,NSC-684766,ET-743, Yondelis)
  • Ecteinascidin
  • Ecteinascidine 743
  • NSC 648766
  • Trabectedin(Ecteinascidin 743,NSC-684766,ET-743)
  • Trabectedin Ecteinascidin
  • Yondelis R ,Trabectedin
  • NSC-684766
  • Trabectedin (Ecteinascidin 743)
  • cteinascidin
  • トラベクテジン
  • エクチナサイジン743
  • エクテイナシジン743
  • エクテイナスシジン743
  • トラベクテジン (JAN)
Copyright 2017 © ChemicalBook. All rights reserved